Discovery of Obacunone as a TGR5 Agonist from Rhizoma coptidis: Affinity Screening, Functional Verification and Transcriptional Analysis

Read full text
Authors: Gaojie Fu, Maoting Liu, Zenghao Bi, Jing Mo, Liang Leng, Dan Sun, Shilin Chen
Cited by: 2
References: 36

Abstract

Rhizoma coptidis (RC), known as Huang Lian, is widely used for treating diabetes in Traditional Chinese Medicine. G protein-coupled bile acid receptor 1 (TGR5) is a potential therapeutic target for glucose-lipid metabolic disorders due to its capacity to stimulate glucagon-like peptide-1 (GLP-1) secretion. However, whether RC contains ingredients targeting TGR5 remains unclear. In this study, we screened 330 secondary metabolites of RC via molecular docking and identified obacunone as a top candidate. We confirmed binding using Cell Membrane Chromatography (CMC) and quantified affinity via Surface Plasmon Resonance (SPR), determining a KD of 101 μM. cAMP assays identified obacunone as an activator of TGR5. Subsequently, concentration-dependent cAMP assays characterized it as a partial agonist with an EC50 of 9.6 μM. Finally, transcriptomic profiling revealed a stress adaptation response, identifying Heme Oxygenase 1 (HMOX1) as the most significantly upregulated gene (padj = 9.99 × 10−72, log2FoldChange = 1.65). These findings contribute to understanding the pharmacological profile of RC and provide a screening example for identifying components with GPCR activity in RC.

Fields of Study & Subjects

Berberine and alkaloids research Diabetes Treatment and Management Drug Transport and Resistance Mechanisms

Publication details

Journal / source
International Journal of Molecular Sciences
Publisher
MDPI AG
Volume
27
Issue
4
Pages
1947–1947
Publication date
18 February 2026
Language
EN